ZC3H7A Antibody

Overview

ZC3H7A (Zinc Finger CCCH-Type Containing 7A, also known as ZC3H7; HSPC055; ZC3HDC7), a member of CCCH gene family, is located on human chromosome 16p13.13. ZC3H7A is associated with some diseases, including Endometrial Stromal Tumor and Endometrial Stromal Sarcoma. An important paralog of this gene is ZC3H7B. The CCCH zinc finger motif has been found in proteins from organisms ranging from man to yeast. The CCCH proteins are a large family of zinc finger containing C3H-type motifs and much evidences proved that they may be RNA-binding proteins functioning in RNA processing. In mouse, tristetraprolin, a protein containing two CCCH zinc fingers, binds directly to AU-rich elements within the 3'-untranslated region of target transcripts to facilitate mRNA degradation. Zfp36l2, like its better-known relative TTP, is a mRNA-binding and destabilizing protein, functions in the physiological control of female fertility at the level of early embryonic development. The PIE-1 is an essential regulator of Caenorhabditis elegans germ cell fate that segregates with the germ lineage by inhibition of transcription or activation of protein expression from maternal RNAs.

This anti-ZC3H7A antibody is supplied as Antigen affinity purified (Rabbit, Polyclonal (rabbit origin), Rabbit IgG, Unconjugated) and is designed to support common target-detection workflows after the on-page specifications.

Key elements and design rationale

• Target: ZC3H7A
• Format: Antigen affinity purified
• Localization: Nuclear, cytoplasmic
• Species reactivity: Human
• Applications (listed): WB, IF, FACS, Direct ELISA
• Conjugate: Unconjugated
• Clone and antibody class: Polyclonal (rabbit origin), Rabbit IgG

Because antibody performance can depend on epitope context, sample preparation, and biological state, interpret signals using appropriate controls and orthogonal evidence when possible.

Biological background

ZC3H7A is referenced in public gene/protein resources (e.g., UniProt and NCBI Gene), which provide curated names/synonyms, protein features, and pathway context. When designing assays, consider potential isoforms, post-translational modifications, and cell-type specific expression that may influence observed signal.

Research relevance and current trends

• Profiling ZC3H7A expression across model systems, perturbations, and time points to support mechanistic hypotheses.
• Combining antibody-based detection with multi-omics or imaging readouts to link ZC3H7A signal with phenotype.
• Using well-matched controls (isotype controls, genetic perturbations, or independent reagents) to strengthen interpretation of target-associated signal.

Common research applications

• WB
• IF
• FACS
• Direct ELISA

Use the listed applications as a starting point and tailor experimental design to your sample type and readout requirements.

Notes for experimental interpretation

• Specificity considerations: closely related family members, isoforms, or PTMs can affect apparent specificity; confirm with independent approaches when critical.
• Controls: include negative controls and, when feasible, genetic or pharmacologic perturbations to support target attribution in your system.
• Species and sample context: differences in sequence, expression, fixation, or extraction conditions can change signal behavior across models.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.